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ABSTRACT 
 
Two different zinc oxide nanoparticles, as well as zinc ion, are used to study the cellular 
responses of the RAW264 macrophage cell line. A proteomic screen is used  to provide 
a wide view of the molecular effects of zinc, and the most prominent results are cross-
validated by targeted studies. Furthermore, the alteration of important macrophage 
functions (e.g. phagocytosis) by zinc is also investigated. The intracellular 
dissolution/uptake of zinc is also studied to further characterize zinc toxicity. Zinc oxide 
nanoparticles dissolve readily in the cells, leading to high intracellular zinc 
concentrations, mostly as protein-bound zinc. The proteomic screen reveals a rather 
weak response in the oxidative stress response pathway, but a strong response both in 
the central metabolism and in the proteasomal protein degradation pathway. Targeted 
experiments confirm that carbohydrate catabolism and proteasome are critical 
determinants of sensitivity to zinc, which also induces DNA damage. Conversely, 
glutathione levels and phagocytosis appear unaffected at moderately toxic zinc 
concentrations.  
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INTRODUCTION 
 
Zinc oxide nanoparticles are among the most widely used nanoparticles. Apart from 
their possible role in nanomedicine  (e.g. in 1 ), they are also widely used in 
sunscreens 2 or as antibacterials 3. However, zinc oxide nanoparticles are known to 
be toxic in man, as they are for example one of the causal agents of the metal fume 
fever 4. There are also several reports on zinc oxide toxicity on different cellular 
models 5-11.  Although some reports show a clear role for the nanoparticles 
themselves 7,12, several reports demonstrate a clear role of dissolved zinc ion in the 
toxicity of zinc oxide nanoparticles 13-16. As to the role of dissolved zinc ion, some 
reports suggest a major role for extracellular dissolution 11,15, 17, while other reports 
suggest that intracellular dissolution in lysosomes after uptake of nanoparticles is 
predominant 7, 12, 13, 18.  
As to the toxicity mechanisms of zinc oxide nanoparticles, most of the studies imply 
the oxidative stress pathway5, 9, 19, leading to DNA damage 5, 8, although interference 
with ion homeostasis has also been implicated 9,20. However, these are mostly  
targeted studies investigating classical mechanisms in nanoparticles toxicity, and 
studies using wider and less oriented approaches are still rare 21.  
 
Due to their known implication in diseases related to particulate matter such as 
asbestosis 22, 23, and the well-known inflammatory dimension of the zinc oxide-
induced metal fume fever 24,25, myeloid cells and especially macrophages  are a 
typical target cell type when investigating the toxicity of zinc oxide nanoparticles. 
Thus,  myeloid cells have been used in several studies dealing with zinc oxide 
toxicity 6, 11, 21, 26, 27. Most of these studies have concentrated on the classical chronic 
inflammation scheme, and investigated the production of pro-inflammatory cytokines 
upon treatment with zinc oxide. The results are however conflicting, some studies 
describing the production of some cytokines 26,27 while others do not describe any 
cytokine production 6. 
However, a wide scope approach aiming at finding the key responses of 
macrophages  to zinc oxide nanoparticles is still missing, despite the recent 
transcriptomic work recently described 21. This is why we undertook a combined 
targeted and proteomic study of the responses of the mouse macrophage cell line 
RAW264 to zinc ion and to two different types of zinc oxide nanoparticles (coated 
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and uncoated). RAW264 cells are one of the classical macrophage models and have 
been often used for studying the effects of nanoparticles in macrophages (e.g. in 26, 
28-33. They are also one of the few cell lines able to produce NO upon LPS 
stimulation 34, a feature absent from the other classical human macrophage model 
THP-1. The rationale of this comparison was  to check if the coating can modify not 
only the toxicity of the nanoparticle 19, but can also alter the cellular responses to the 
nanoparticles.  
 
 
RESULTS 
 
Nanoparticles characterization  
 
The two commercial nanoparticles were characterized by several methods, and the 
results are summarized in Table 1 and in supplementary figures 1 to 3. The zinc oxide 
nanoparticles were rod shaped, while the cationic coated zinc oxide was more spherical. 
The XRD diagrams conformed to those of nominal zinc oxide, showing no crystalline 
impurities. The zeta potential was positive for both nanoparticles, with the cationic 
coating accounting for an increase in the positive surface charge. Finally, the 
nanoparticles could be dispersed in complete culture medium as aggregates of ca. 200 
nM in diameter.  
In order to verify that the nanoparticles were not degraded prior to their contact with the 
cells, we checked their dissolution in the 50mg/ml intermediate nanoparticules 
dispersion (corresponding to 625mM zinc). Only 1mM dissolved zinc was measured 
after 7 days.  
 
Determination of the effective doses 
 
For carrying out a proteomic study, we had to determine the dose for which we would 
obtain the best compromise between viability and biological effect. We therefore decided 
to use a LD20, i.e. a dose leading to a cell mortality of 20%, knowing that the mortality of 
a control culture is around 5%.   
The LD20 was obtained at 8 µg/ml for the ZnO nanoparticles, 7µg/ml for the coated 
cationic ZnO nanoparticles, and at 120µM for zinc ion (supplementary figure 4). These 
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concentrations were used for the subsequent studies. 
 
Determination of nanoparticles fate in cells 
 
Transmission electron microscopy was performed to determine the fate of the 
nanoparticles when in presence of macrophages. These experiments (Figure 1) showed 
that nanoparticles were present in vacuolar structures identified as multivesicular bodies 
and as lysosomes. These results were in line with what can be expected from 
professional phagocytes. Moreover, these results demonstrate that macrophages seem 
to ingest both nominal nanoparticles and nanoparticles aggregates present in the culture 
medium and to break them down in the endosomes-lysosomes. Indeed, eroded 
nanoparticles can easily be seen (Figure 1B and 1C), demonstrating this intracellular 
erosion phenomenon. 
 
In order to gain further insights into the intracellular zinc concentration, we measured the 
zinc concentration that could be released from a post nuclear supernatant prepared from 
cells exposed to zinc ion  or ZnO nanoparticles. The results, shown in Table 2, 
demonstrate that zinc is concentrated in cells compared to the original input. For 
example, the values obtained with zinc ion convert to an intracellular concentration of 
187± 12.5 µM, while the input is only 100µM zinc in the culture medium. These values 
are orders of magnitude higher than those recently published for the concentrations of 
free zinc ion after exposure to zinc salts and ZnO nanoparticles 20. It should be 
emphasized, however, that the two studies do not measure the same parameter. The 
study using zinc-sensitive fluorescence probes 20 measures only free zinc, and thus 
does not measure zinc complexed to macromolecules (e.g. proteins) whereas our study 
implements a strong protein denaturation step to release protein-bound zinc and to 
measure all intracellular zinc ion. This demonstrates in turn that most intracellular zinc is 
not free but protein-bound, which prompted us to analyze zinc-binding proteins. 
 
Proteomic analyses 
 
Two sets of proteomic analyses were performed. The first one dealt with the quantitative 
analysis of the proteome on whole cell extracts prepared from control cells vs. cells 
exposed to zinc ion or to both types of ZnO nanoparticles. This analysis pointed to the 
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cellular responses to the presence of excess zinc in terms of protein quantitative 
changes. The second type dealt with zinc-binding proteins, providing a list of putative 
targets in case of a zinc overload. This list does not necessarily superimpose to the list 
of zinc-containing proteins under normal zinc load. As the extract used in the affinity 
enrichment is prepared under normal growth conditions, it is highly likely that the bona 
fide zinc binding proteins will be already loaded with zinc and will not bind to the extra 
zinc ion presented via the affinity column. Conversely, we expect to retain on the column 
the proteins that do not necessarily bind zinc under normal conditions, but that can bind 
it when present in excess, i.e. in the conditions prevailing during zinc overload.  
 
The proteomic analysis of whole cell extracts is detailed in Figure 2 and Table 3 . With 
2780 reproducibly detected spots, and using an average of 3 spots per protein 35 this 
proteomic screen probed the proteome to a depth of ca 900 gene products, i.e. ca.15% 
of the total proteome. Despite this rather limited depth, we could detect reproducible 
modulations forproteins belonging to several functional classes. The median coefficient 
of variations of spots was 28%, i.e. marginally higher than in typical 2D DIGE 
experiments, where coefficient of variations range from 18 to 28%, depending on the 
sample 36-39. The protein changes were detected through the use of a variance-based 
screen 40. Compared to a fold-change screen, this process compensates  automatically 
for the variance of each spot. This excludes automatically spots with a high coefficient of 
variation, but enables to take into account small but reproducible changes when the 
coefficient of variation is low, thus avoiding the arbitrary exclusion of changes that can 
be biologically meaningful 40. As an example, the endoplamic reticulum protein ERP29 is 
selected as significantly modulated, although the fold change is only 0.8 fold. This is due 
to the fact that the coefficient of variation of this spot is only 8% in the control group and 
4% in the zinc ion-treated group.  
 
Metabolic enzymes, cytoskeletal proteins and proteins implicated in the proteasomal 
degradation are strongly represented in the list of modulated proteins. Moreover, more 
than a third of these modulated proteins (17/45) are significantly changed only by the 
zinc ion, but not by the nanoparticles. Very few proteins (4) are significantly changed by 
the three treatments, and very few are specific of one type of nanoparticles (4 for zinc 
oxide and 3 for cationic zinc oxide).  It is also interesting to compare our proteomic 
results to the transcriptomic results recently published on immune cells and zinc oxide 
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21. Only two proteins (ERP29, spot F1, and major vault protein, spot C8) are found in 
common between our list of modulated proteins and the list of modulated mRNAs in 
macrophages, an additional four proteins being found in common with modulated RNAs 
in Jurkat cells (ADSS spot N2 , DLAT spot M3, GCLM spot O2,  and calcyclin-binding 
protein spot D2).  
 
The proteomic analysis of zinc binding proteins is detailed in Figure 3 and Table 4. First, 
it should be noted that the background given by an "empty" resin (i.e. without a bound 
metal) was extremely low, as a basically empty 2D gel was obtained (data not shown). 
However, to minimize any possible bias, the experiments were carried out on three 
different biological replicates and only the proteins significantly enriched in the zinc 
column compared to the starting extract (p≤ 0.05) were further analyzed and listed in 
Table 2. Here again, metabolic enzymes and cytoskeletal proteins were strongly 
represented. The two tables show a low overlap, however, pointing out the 
complementarity of the two analyses. 
 
Validation studies 
 
The inclusion of small but reproducible protein changes means in turn that these 
changes cannot be validated easily  by classical biochemical techniques at the protein 
expression level. For example, protein blotting often shows a technical variability well 
above 20%, and  a response curve often lower than the one of 2D electrophoresis (e.g. 
in38), making this technique unsuitable for the validation of small fold changes. This 
renders functional validation even more necessary 41, to confirm the biological relevance 
of the proteomically detected protein modulations.  
 
Characterization of the oxidative stress response 
 
Oxidative stress is now used as a toxicological marker for almost all toxicants, and zinc 
ion and zinc oxide are no exception to this rule 5, 14. However, we did not detect any 
change in the classical oxidative stress response proteins, as opposed to what was 
observed with copper oxide nanoparticles 42. Nonetheless, we detected an increase in 
two non classical proteins that can be involved in the antioxidant response, namely flavin 
reductase (spot O3) and glutamate cysteine ligase (GCLM, spot O2). The latter protein 
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is of interest, as it controls the limiting step in glutathione biosynthesis. Furthermore, 
glutathione depletion has been suggested as an important mechanism in zinc toxicity 43. 
We therefore measured the intracellular levels of reduced glutathione by a 
monochlorobimane conjugation approach 44. The results, shown on Figure 4A, 
demonstrate a moderate but reproducible increase in GSH levels, validating the 
increase of GCLM detected via proteomics (fold change 1.6 to 1.8 in Table 3). This 
suggests that macrophages are able to counteract the GSH chelation due to zinc ion by 
de novo synthesis of glutathione, a situation quite different from the one observed in 
neurons 43.  
Another interesting protein detected via our proteomic screen and involved in the 
oxidative stress response is the flavin/biliverdin reductase (spot O3), which reduces 
biliverdin into bilirubin. This bilirubin/biliverdin cycle has been implied in hydrogen 
peroxide destruction 45. As this protein has a detectable enzymatic activity, we decided 
to confirm the proteomic result by a direct assay of the biliverdin reductase activity 
(Table 5). A significant induction was observed, as detected by the proteomic screen.  
 
Characterization of the phagocytic response 
 
As we observed several changes in proteins involved in the actin (e.g. ARP proteins 
spots C5 and C9,  lsp1 protein spot C3, glia maturation factor spot C1, twinfilin spot C4 
or gelsolin spots C7) and tubulin cytoskeleton (MAPRE1spot C2 and TCP1 spot C6), we 
could anticipate perturbations in the phagocytic capacity of zinc-treated macrophages. 
We thus assessed this important function of macrophages upon treatment with zinc ion 
or ZnO nanoparticles. The results, presented on Figure 4B, show that macrophages are 
still highly phagocytic even when treated with zinc, as long as the concentrations remain 
non toxic.  
 
DNA damage 
 
As several nanoparticles have been shown to induce DNA damage 8, 46-48, we decided to 
test whether zinc-based nanoparticles can induce DNA damage, using an alkaline comet 
assay. The results, shown on Figure 5, demonstrate that zinc  ion, zinc oxide but not 
cationized zinc oxide, are able to induce DNA damage even at the moderately toxic 
LD20 dose. This also confirms previous results , e.g. on normal nasal mucosa cells 8. 
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Metabolic perturbations 
 
Our proteomic screens highlighted several proteins implicated in energy metabolism, 
and more specifically in the glycolysis and pentose phosphate pathways (spots E1 to 
E5). These proteins were found in both screens, i.e.  proteins responding to the zinc 
stress and zinc-binding proteins. In fact, several important energy metabolism enzymes 
have been shown to bind zinc and be inhibited by it 49-51.  
We proceeded to a two step validation. First, the enolase and 6-phosphogluconate 
dehydrogenase activities were measured (Table 5). Here again, the enzymatic activities 
confirmed the proteomic results, showing an increase upon treatment of the cells with 
zinc. As the 6-phosphogluconate dehydrogenase was also found in the zinc binding 
proteins, we hypothesized that it could be inhibited by zinc in the context of a complete 
cell extract, and not only as a purified protein 52 . We therefore assayed the 6-
phosphogluconate dehydrogenase activity in the presence of added zinc acetate, and 
found an IC50 close to 12µM. As this concentration is much lower than the one detected 
in our cell extracts upon zinc treatment, it can be reasonably hypothesized that the 
pentose phosphate pathway is impaired during zinc overload. This could contribute to 
the observed oxidative stress, as the pentose phosphate pathway is a major source of 
NADPH, required by many reductases implied in the defense against oxidative stress 
(e.g. glutathione reductase, biliverdin reductase and thioredoxin reductase). In contrast, 
GAPDH was marginally inhibited by zinc, with only 30% inhibition at 100µM zinc (data 
not shown).  
 
Finally, we tested the final metabolite of the pentose phosphate and glycolysis 
pathways, i.e. pyruvate. First, zinc stress induced a higher level of pyruvate in cells, as 
shown in Figure 6A. This is in line with the activation of the glycolytic metabolism 
observed in occupational medicine 53, and suggested that pyruvate is a critical 
metabolite for survival in presence of a zinc stress, as in neuronal cells 54, 55. Our results 
demonstrate that pyruvate acts as a survival factor upon zinc stress, both for zinc ion 
(Figure 6B), zinc oxide (Figure 6C) and cationized zinc oxide (Figure 6D). Thus, energy 
metabolism is one of the crucial determinants in resistance to zinc.  
 
Our proteomic screens also highlighted several proteins of the proteasomal degradation 
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pathway  such as proteasome subunits (spots D4 and D6) and proteins implicated in the 
ubiquitination step (spots D5 and D1 to D3). In order to investigate the putative 
implication of this pathway in the response to zinc, we assessed the survival to zinc 
treatment after proteasome inhibition with the inhibitor MG132. The results, shown on 
Figure 7, demonstrate that proteasome inhibition increases zinc toxicity, which can be 
attributed to a synergistic effect between the inhibition of the proteasome by MG132 and 
the known inhibition of the proteasome by zinc 56.  
 
DISCUSSION 
 
When taken together, the results of both the proteomic and targeted experiments 
produce a landscape of the cellular response to zinc. Opposite to what has been 
observed with copper 42, zinc ion and zinc oxide do not induce by themselves a 
strong oxidative stress. This is consistent with the fact that zinc, unlike copper, iron 
or manganese, cannot undergo redox cycles between ions of different valency. 
Thus, the almost generic oxidative stress that has been observed with zinc oxide 5, 
14, can be attributed to a more general perturbation leading to an imbalance in 
cellular redox cycles and thus to ROS production. 
 
From our results, a key determinant in zinc toxicity appears to be a general 
metabolic perturbation. Many carbohydrate catabolic enzymes are either induced 
upon zinc treatment (Table 1) or bind to zinc (Table 2), and the overall result is both 
an increase in pyruvate production and the evidence that pyruvate is a critical 
metabolite for cell survival during zinc treatment. This is in line with previous studies 
on neuronal cells 51, and suggests that an important determinant in zinc toxicity is a 
metabolic impairment leading to an "energy shortage" in zinc-treated cells, leading 
eventually to cell death. 
 
Along a closely related line, the number of proteins able to bind zinc ions and the 
importance of a correct proteasome function also suggests an unfolded protein 
response. Indeed, if taking an average Mw of 50,000 for proteins, a 5mg/ml solution 
of proteins represents a 100µM protein concentration, to be compared with the 30µM 
zinc detected in these extracts upon zinc overload. Consequently, many proteins 
binding zinc when present in excess may become ill-folded due to zinc binding, and 
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therefore  degraded through the proteasomal pathway. This would explain in turn 
why proteasome function is also an important parameter in zinc tolerance. This role 
of the proteasome may also explain why zinc, acting as a proteasome inhibitor 56 
also synergizes with prooxidants 57, which also induce a strong unfolded protein 
response.  
 
Furthermore, our results also shed light on the controversy between the roles of 
extracellular and intracellular dissolution of the zinc oxide nanoparticles to explain 
the toxic mechanisms observed. The responses to the zinc oxide nanoparticles are 
included in the responses to zinc ion, which induces further specific responses. This 
supports the hypothesis that the main determinant of zinc oxide toxicity is the zinc 
ion resulting from nanoparticles dissolution. However, the fact that zinc oxide 
nanoparticles are still visible in the cells after 24 hours of treatment suggests that 
uptake of nanoparticles and intracellular dissolution within the cells may be a key 
determinant of zinc toxicity, at least in macrophages. The situation may be indeed 
quite different in cells with a very low endocytic/phagocytic activity, such as T 
lymphocytes 17.  
 
Last but not least,  when comparing in detail the results obtained on copper oxide 42 
and on zinc oxide in the RAW264 cell line, very few common features emerge, 
although both types of nanoparticles show close toxicity. This clearly demonstrates, 
if further needed, that each nanoparticle will induce different toxic mechanisms and 
different cell responses. In this context, zinc seems to act as a general toxicant, 
acting on central cellular pathways, so that cells are metabolically impaired but still 
functional as long as they are alive. Conversely, copper seems to act as a more 
subtle toxicant, leading to cells that are still alive but functionally impaired.  
 
CONCLUSIONS 
 
When trying to understand the toxicity of zinc nanoparticles in macrophages, the fact 
that nanoparticles are detected in the cells argues in favor of a model where the 
nanoparticles are first internalized, then intracellularly dissolved, releasing zinc ion 
that is the real toxicant. As cells seem to be relatively permeable to zinc, the 
molecular effects of the nanoparticles can also be reproduced with zinc ion, even 
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when dealing with large scale screens such as proteomic analyses. Our analyses 
also show that zinc toxicity is produced by a strong uptake of zinc in a protein-bound 
form up to sub-micromolar concentrations, leading to impairment of central 
metabolism and thus to energy shortage in the cell, and also very likely to an 
unfolded protein response. As proteasome is also inhibited by zinc, the proteasome 
pathway becomes an important determinant of zinc resistance.  
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EXPERIMENTAL SECTION 
 
Most of the experiments were performed essentially as previously described 42 and 
the detailed procedures can be found in the supplementary material and methods 
 
Nanoparticles  
 
Zinc oxide nanoparticles, coated or not, were purchased from Sigma-Aldrich (catalog 
numbers 721077 and 677450 respectively). The aminopropyl silane coated particles, 
representing a product used in solar screens, were used as purchased. The 
uncoated zinc oxide nanoparticles were  dispersed in water as a 5% w/v suspension  
by sonication for 60 minutes in a cup-horn instrument (BioBlock Scientific, 
Strasbourg, France) , under a 5°C thermostated water circulation. The actual size of 
the particles was determined after dilution in water or in complete culture medium by 
dynamic light scattering, using a Wyatt Dynapro Nanostar instrument. A Malvern HS 
3000 instrument was also used to determine the zeta potential. The crystalline 
phases were identified using a powder diffractometer from Bruker  and the Match 
software (crystal impact).  The morphology of samples was observed by SEM 
(Scanning Electron Microscopy) and TEM (Transmission Electron Microscopy) after 
dispersion of the nanoparticles in water using an ultrasonic bath and deposition of a 
droplet on 200 mesh carbon lacey grids. The weight loss (from about 10mg of 
sample) was evaluated from annealing under air using a Thermogravimetric Analysis 
device (Setaram). The temperature cycle was heating at a rate of 10°C/min up to 
1000°C followed by a dwelling time of 30 minutes and natural cooling. 
To measure nanoparticles dissolution in the 50 mg/ml intermediate dispersion used  
prior to addition in the cell cultures, the dispersion was centrifuged at 270,000g for 
45 minutes to sediment the nanoparticles  58. 
The dissolved zinc concentration in the supernatant was then determined, after the 
appropriate dilution in water, by a xylenol orange colorimetric assay 59, using 0.1M 
MES buffer pH 6 and 60µM xylenol orange as an indicator. 
 
 
Nanoparticles dissolution  in cells 
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For the studies on cell extracts, the cells were treated with zinc oxide nanoparticles 
for 24 hours prior to harvest. The cells were then recovered by scraping, collected by 
centrifugation, washed three times with PBS, and the volume of the cell pellet was 
determined. A cell lysis solution (Hepes 20 mM pH 7.5, MgCl2 2 mM, KCl 50 mM, 
tetradecyldimethylammonio propane sulfonate (SB 3-14) 0.15% w/v) was added at a 
ratio of 5 volumes of solution per volume of cell pellet, and the cells were left to lyse 
on ice for 20 minutes. The suspension was then centrifuged at 1000g for 5 minutes, 
the supernatant collected, and recentrifuged at 270,000g for 45 minutes to sediment 
the nanoparticles  58. 
 
Zinc concentration was then determined using an adapted xylenol orange 
colorimetric assay 59. Briefly, 1 ml of medium/cell extract was first cooled in an ice 
bath for 30 minutes. TCA was added to a 5% w/v final concentration, and the mixture 
was left for 1 hour on ice to denature the proteins and release complexed zinc ion. 
The mixture was centrifuged for 10 minutes at 15,000g, the supernatant recovered 
and its volume measured. A neutralizing solution (2 M MES-Na salt) was added 
(0.25 volume/volume of supernatant) was added, followed by 0.03 volume of a 2 mM 
xylenol orange solution in water. The color was left to develop for 5 minutes and the 
absorbance measured at 565 nm. Under these conditions, no interference was 
observed with magnesium, calcium or iron. As the extract is diluted 5fold compared 
to the initial cell volume, the concentration read in the assay is multiplied by 5 to 
obtain the intracellular zinc concentration. 
 
Cell culture 
 
The mouse macrophage cell line RAW 264.7  was obtained from the European Cell 
Culture Collection (Salisbury, UK). The cells were cultured in RPMI 1640 medium + 
10% fetal bovine serum. Cells were seeded at 200,000 cells/ml and harvested at 
1,000,000 cells per ml. For treatment with zinc ion or zinc oxide nanoparticles, cells 
were seeded at 500,000 cells/ml. They were treated with zinc on the following day 
and harvested after a further 24 hours in culture. Cell viability was measured by the 
neutral red uptake assay 60.  All experiments were carried out at least in triplicate on 
independent cultures.  
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Phagocytosis activity measurement 
 
The phagocytic activity was measured after treatment with zinc using fluorescent 
latex beads (1µm diameter, green labelled, catalog number L4655 from Sigma) and 
flow cytometry, essentially as described in 6142. 
 
Transmission Electron Microscopy 
 
Transmisson electron microscopy was carried out as previously described 42  on 
cells fixed with glutaraldehyde, included in Epon and post stained with lead citrate 
and uranyl acetate.   Energy dispersive X-ray (EDX) analysis was performed on 
sample sections. Spectra were obtained using a large angle SDD-EDS  attached to a 
Jeol 2010 TEM. 
 
 
Intracellular glutathione measurements 
 
Intracellular glutathione levels were analyzed by the monochlorobimane technique  
44, with some modifications 6242. 
 
 
Pyruvate assay 
The pyruvate content of cells was determined using the pyruvate assay kit from 
Sigma (ref # MAK071), used according to the manufacturer instructions. 
 
Enzyme assays 
The enzymes were assayed according to published procedures. Enolase was 
assayed by the direct conversion of 2-phosphoglycerate into phosphoenolpyruvate, 
detected at 240nm 63.6-phosphogluconate dehydrogenase was assayed by a 
coupled assay using Nitro blue tetrazolium as the final acceptor and phenazine 
methosulfate as a relay 64. Biliverdin reductase was assayed directly for the NADPH-
dependent conversion of biliverdin into bilirubin, followed at 450nm 45.  
The cell extracts for enzyme assays were prepared by lysing the cells for 20 minutes 
at 0°C in Hepes 20 mM pH 7.5, MgCl2 2 mM, KCl 50 mM, EGTA 1 mM, SB 3-14 
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0.15% w/v, followed by centrifugation at 15,000g for 15 minutes to clear the extract. 
The protein concentration was determined by a dye-binding assay 65.  
For the zinc inhibition studies, the cell extracts were first diluted in the assay buffer 
(final protein concentration 0.2 mg/ml), supplemented with defined concentrations of 
zinc acetate. The resulting solutions were incubated at 37°C for 30 minutes to allow 
zinc binding. The substrates and cofactors were then added and the activity 
measured spectrophotometrically.  
 
Comet assay 
The comet assay was performed essentially as described in Jugan et al. 46. Briefly, 
microscope slides were coated with 1% normal melting point agarose (NMA) and 
allowed to dry. Around 10,000 cells (75 µL of each cell suspension) were mixed with 
0.6 % low melting point agarose (LMPA) and deposited over the agarose layer, and 
the LMPA/cells mix was allowed to solidify on ice. The slides were immersed 
overnight in cold lysis solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% SDS, 
10% DMSO, 1 % Triton X-100) at 4°C. DNA was then allowed to unwind for 30 min 
in alkaline electrophoresis solution (300 mM NaOH, 1 mM EDTA, pH > 13). 
Electrophoresis was performed in a field of 0.7 V/cm and 300 mA current for 30 min. 
Slides were then neutralized with 0.4 M Tris pH 7.5 and stained with 50 µL of 20 
µg/ml ethidium bromide. At least 50 comets per slide were analyzed under a 
fluorescence microscope (Zeiss) equipped with a 350-390 nm excitation and a 456 
nm emission filter at ×20 magnification. Comet length and intensity were measured 
by using Comet IV software (Perceptive Instruments, Suffolk, UK). 
 
Proteomics 
 
Sample preparation, 2D gel analysis and mass spectrometry were performed 
essentially as previously described 42 and the detailed procedures can be found in 
the supplementary material and methods. Thus, only the specific methods will be 
described in detail in this section 
 
Sample preparation: zinc-binding proteins 
 
Zinc-binding proteins were prepared by an affinity enrichment, using zinc ion loaded 
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onto iminodiacetic agarose (Sigma#I4510). One milliliter of gel suspension was 
diluted with one milliliter of gel suspension buffer (Hepes 20 mM pH 7.5, KCl 50 
mM), incubated for 10 minutes in a cold room on a rotating wheel, and centrifuged at 
10,000g for 10 minutes. The gel pellet was then resuspended in 1.5 ml of gel 
suspension buffer, and the agitation-centrifugation cycle was repeated. The gel pellet 
was then resuspended in 1.5 ml of gel suspension buffer, to which zinc acetate was 
added at a final concentration of 0.1 M. The suspension was agitated on the rotating 
wheel (cold room) for 30 minutes, then centrifuged as described above. Five rinsing 
cycles (suspension in 1.5 ml of gel suspension buffer, rotating wheel for 15 minutes, 
centrifugation) were then applied. The gel was ready for use after the last 
centrifugation. 
 
The native cell extract was prepared as follows: Cells were collected by scraping, 
centrifuged (200g for 5 minutes), and rinsed three times with PBS. The cell pellet 
volume was estimated, a cell lysis solution (Hepes 20 mM pH 7.5, MgCl2 2mM, KCl 
50 mM, tetradecyldimethylammonio propane sulfonate (SB 3-14) 0.15 % w/v, 
phenylmethylsulfonyl fluoride1 mM and iodoacetamide  1 mM) was added at a ratio 
of 5 volumes of solution per volume of cell pellet, and the cells were left to lyse on 
ice for 20 minutes. The suspension was then centrifuged at 1000 g for 5 minutes, the 
supernatant collected, and the protein concentration determined by a dye-binding 
assay 65.  
 
One milligram of proteins was loaded onto 0.2 ml of zinc-loaded iminodiacetic 
agarose, and the final volume was brought to 1.5 ml with gel suspension buffer. The 
proteins were left to adsorb overnight (rotating wheel, cold room). The gel was 
collected by centrifugation (10,000g 10 minutes), and six rinsing cycles (suspension 
in 1.5 ml of gel suspension buffer, rotating wheel for 15 minutes, centrifugation) were 
then applied. SB 3-14 (0.1% final concentration) was added to the rinsing buffer for 
the first four cycles. After the final centrifugation, four volumes (respective to the gel 
volume) of concentrated lysis buffer (urea 8.75 M, thiourea 2.5 M, 3-[3- 
Cholamidopropyl]-dimethylammoniopropane-1-sulfonate (CHAPS) 5% w/v, 
tris(carboxyethyl)phosphine-HCl 6.25 mM, spermine base 12.5 mM) were added and 
the solution was let to extract at room temperature for 1 hour. The gel was removed 
by centrifugation (15,000g, 20 minutes) and the protein concentration in the 
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supernatant was determined by a dye-binding assay. Carrier ampholytes 
(Pharmalytes pH 3-10) were added to a final concentration of 0.4% (w/v), and the 
samples were kept frozen at -20°C until use. 
 
2D gel electrophoresis 
 
Isoelectric focusing was carried out on home made 160 mm long 4-8 linear pH gradient 
gels 66, cast according to published procedures  67, and rehydrated overnight with the 
sample in 7 M urea, 2 M thiourea, 4% CHAPS, 0.4% carrier ampholytes (Pharmalytes 3-
10) and 100 mM dithiodiethanol 68,69. 
IEF strips were run for 60-70 kVh (see supplementary material and methods for details), 
equilibrated for 20 minutes in Tris 125mM, HCl 100mM, SDS 2.5%, glycerol 30% and 
urea 6 M 70, and transferred on top of the SDS gels. 
Ten percent gels (160x200x1.5 mm) were used for the second dimension. The Tris 
taurine buffer system 71 was used and operated at a ionic strength of 0.1 and a pH of 
7.9. Detection was carried out by fast silver staining 72.  
 
Image analysis 
 
The gel images were analyzed using the Delta 2D software (v 3.6). Three gels coming 
from three independent cultures were used for each experimental group. Spots that 
were never expressed above 100 ppm of the total spots were first filtered out. Then, 
significantly-varying spots were selected on the basis of their Student T-test p-value 
between the treated and the control groups. Spots showing a p-value lower than 0.05 
were selected.  
 
Mass spectrometry 
 
The spots selected for identification were analyzed by NanoLC-MS/MS analysis, 
performed using a nanoLC-QTOF-MS system and a nanoLC-IT-MS system operated as 
described previously 42 (details can also  be found in  the supplementary material).  
The MS/MS data were interpreted using MASCOT 2.4.0 (Matrix Science, London, UK) 
against UniProtKB/SwissProt (version 2012_08, 537,505 sequences). The search was 
carried out in all species. A maximum of one trypsin missed cleavage was allowed. 
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Spectra from Qtof were searched with a mass tolerance of 15 ppm for MS and 0.05 Da 
for MS/MS data and spectra from Ion Trap were searched with a mass tolerance of 0.3 
Da in MS and MS/MS modes. Carbamidomethylation of cysteine residues and oxidation 
of methionine residues were specified as variable modifications. Protein identifications 
were validated with at least two peptides with Mascot ion score above 20. 
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Figure 1: Transmission electron microscopy analysis of nanoparticles-treated cells 
(A) TEM image of a RAW 264 cell exposed to zinc oxide. (B) A higher magnification 
of the boxed area in A is shown ( flipped 180°) and the arrow points to nanoparticles 
concentrated in multivesicular bodies. (C) Electron-dense particles resembling zinc 
oxide were observed in a multivesicular body by TEM and (D) the corresponding 
EDX spectrum, indicating the presence of zinc (arrows) which appears overlapping 
with a background generated from other elements present in the sample (copper for 
the grids and osmium for the cell post-fixation step). 
 
A similar internalisation was also observed for the cationic coated zinc oxide 
nanoparticles (data not shown) 
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Figure 2: Proteomic analysis of total cell extracts by 2D electrophoresis 
 
Total cell extracts of RAW264 cells were separated by two-dimensional gel electrophoresis. 
The first dimensions covered a 4-8 pH range and the second dimension a 15-200 kDa 
range. Total cellular proteins (150 µg) were loaded on the first dimension gel.  
 
A: gel obtained from control cells 
B: gel obtained from cells treated with cationic zinc oxide (7 µg/ml, 24 hours) 
 27 
C: gel obtained from cells treated with zinc oxide (8 µg/ml, 24 hours) 
D: gel obtained from cells treated with zinc ion (120 µM, 24 hours) 
 
The arrows point to spots that show reproducible and statistically significant changes 
between the control and zinc-treated cells. Spot numbering according to Table 3. 
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Figure 3: Proteomic analysis of zinc-binding proteins by 2D electrophoresis 
 
Cell extracts of RAW264 cells were separated by two-dimensional gel electrophoresis. The 
first dimensions covered a 4-8 pH range and the second dimension a 15-200 kDa range. 
Two hundred micrograms of proteins were loaded on the first dimension gel.  
 
A: analysis of the total post nuclear supernatant 
B: eluate from the Zn-iminodiacetic sepharose column 
 
The arrows point to spots that show a reproducible and statistically significant increase in 
the column eluate compared to the starting extract. Spot numbering according to Table 4. 
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Figure 4:  Functional alterations of macrophages upon zinc treatment 
 
RAW264 cells were treated for 24 hours with the indicated zinc compounds. In the 
top panel, the intracellular concentration of reduced glutathione is indicated.  The 
results are expressed in percentage of the activity of control cells. 
 
In the bottom panel,  the phagocytic activity index of the cells is indicated. Solid bars, 
activity at 37°C, hatched bars, background measurements at 4°C. The results are 
expressed in percentage of the activity of control cells at 37°C 
 
Both measurements were carried out in triplicate. Statistical confidence (Student T-
test) is indicated as follows: *: p ≤ 0.05; ** p ≤ 0.01; *** p≤ 0.001 
 
  
 30 
 
 
Figure 5: assessment of DNA damage 
Damages to DNA on RAW264 cells after zinc treatment was evaluated using the 
alkaline version of the comet assay, taking into account both single and double 
strand breaks. The results are expressed in percentage of DNA in the tail. 
Butylhydroperoxide (BHP) was used as a positive control. 
 
Measurements were carried out in triplicate (except for BHP where n=1). Statistical 
confidence (Student T-test) is indicated as follows: *: p ≤ 0.05; ** p ≤ 0.01; *** p≤ 
0.001 
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Figure 6: Role of pyruvate as a survival factor during zinc treatment 
In panel A, RAW 264 cells were treated for 24 hours as indicated. The pyruvate 
content of the cells was measured and normalized to the number of cells after 
harvest.  
In panels B to D, cells were pretreated with 4 mM pyruvate (circles) or not (squares) 
for 6 hours before treatment for a further 18 hours with zinc as indicated. Cell 
survival is indicated as the percentage of untreated cells. B: zinc ion; C: zinc oxide; 
D: cationic zinc oxide 
 
Experiments were carried out in quadruplicate. Star denotes statistically significant 
differences (p ≤ 0.05 in the Mann Whitney U test) 
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Figure 7: Role of proteasome as a survival factor during zinc treatment 
RAW 264 cells were pretreated with 100 nM MG132 (circles) or not (squares) for 6 
hours before treatment for a further 18 hours with zinc as indicated. Cell survival is 
indicated as the percentage of untreated cells. A: zinc ion; B: zinc oxide; C: cationic 
zinc oxide. 
Experiments were carried out in quadruplicate. Star denotes statistically significant 
differences (p ≤ 0.05 in the Mann Whitney U test) 
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Table 1 : Characterization of the two zinc oxide nanoparticles used in this study 
 
 
 
ZnO Cationic coated ZnO 
   Shape rod spheroid 
size of primary particles (TEM) 117±22nm x 49±16nm 32±8 nm 
zeta potential 23.5 mV 35 mV 
XRD conform conform 
crystaline domain size (XRD)  ca.51 nm  ca.25 nm 
percentage in mass of organic matter (coating) NA 11.5% 
average size (diameter) in water (DLS) 245nm 145nm 
average size (diameter) in culture medium 250nm 215nm 
Dissolved zinc in the 50mg/ml working suspension 0.93 ± 0.12 µM 1.19±0.37µM 
 
 
Table 2 : intracellular uptake of zinc under the different conditions 
 
 
Input in cell culture Concentration Concentration 
 
in cell extract in cells 
   
   Cationic zinc oxide (90µM) 27±7µM 135±35 µM 
Zinc acetate (100µM) 37.5±2.5 µM 187.5±12.5 µM 
Zinc oxide (100µM)  30±1µM 150±5 µM 
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Table 3: Differentially-expressed proteins identified in the proteomic screen 
 
spot protein name accession ZnOcat /ctrl ZnO /ctrl 
Zn 
ion/ctrl 
nb. of sequence  
ID number* fold/T-test fold/T-test 
fold/T-
test 
unique coverage 
  
     
peptides   
F: folding 
     
  
F1 Endoplasmic reticulum resident protein 29 P57759 1.003/98 1.008/92 0.808/4 6 24% 
F2 Prefoldin 3 P61759 1.111/59 0.599/9 0.645/8.4 3 21% 
  
      
  
C: cytoskeleton 
     
  
C1 Glia maturation factor gamma  Q9ERL7 0.753/19 0.486/18 0.620/7.4 5 39% 
C2 Microtubule-associated protein MPREB1 Q61166 0.969/73 0.872/14 0.809/3.4 7 40% 
C3 Lymphocyte-specific protein 1 P19973 0.815/10 0.824/5 0.755/3 5 21% 
C4 Twinfilin-2 Q9Z0P5 0.835/36 0.832/36 0.755/3 6 22% 
C5 Actin-related protein 2 P61161 0.855/8 0.841/12 0.862/9 10 29% 
C6 T-complex protein 1 subunit gamma  P80318 1.022/84 0.988/99 0.618/2 6 12% 
C7a Gelsolin P13020 1.26/41 1.50/5 1.28/39 6 8% 
C7b Gelsolin P13020 1.22/44 1.51/6 1.22/41 4 8% 
C7c Gelsolin P13020 1.28/31 1.65/2 1.35/22 5 7% 
C7d Gelsolin P13020 1.45/37.2 1.876/6 1.569/18 11 17% 
C7e Gelsolin P13020 1.72/25 2.3/4 17/18 6 8% 
C8 Major vault protein Q9EQK5 1.643/4.1 1.599/7 1.469/10 12 17% 
C9 Actin-related protein 3 Q99JY9 1.23/3 1.19/11 1.25/18 5 15% 
  
      
  
  
      
  
D: degradation 
     
  
D1 Ubiquitin-conjugating enzyme E2 N P61089 0.734/19 0.600/3 0.741/1.3 3 27% 
D2 Calcyclin-binding protein Q9CXW3 1.111/67 1.072/22.4 0.862/5 7 30% 
D3 Ubiquitin carboxyl-terminal hydrolase  L3 Q9JKB1 0.667/7 1.024/88 0.58/10 3 14% 
D4 Proteasome activator complex subunit 2 P97372 0.943/33 0.98/86 0.832/1.3 6 37% 
D5 Ubiquitin carboxyl-terminal hydrolase L5 Q9WUP7 0.972/73 0.908/8.4 0.495/2 8 32% 
D6 26S protease regulatory subunit 7 P46471 0.761/13 0.762/11.3 0.518/2.2 3 8% 
  
      
  
  
      
  
S: signalling 
     
  
S1 Growth factor receptor-bound protein 2 Q60631 0.622/14.5 0.666/3 0.466/2 4 16% 
S2 G nucleotide-binding protein beta-2 P62880 0.866/34 0.892/13 0.638/1.6 4 13% 
S3 G nucleotide-binding protein alpha-2 P08752 0.878/19 0.848/12 0.712/2.4 5 21% 
S4 GNB protein subunit beta-2-like 1 P68040 1.719/3.2 1.674/7.9 1.54/8.1 11 42% 
S5 PP2A 2A 65 kDa scaffold subunit A alpha Q76MZ3 1.087/52 1.246/4 1.177/15 5 19% 
  
      
  
  
      
  
N: nucleotide metabolism 
     
  
N1 Adenine phosphoribosyltransferase  P47957 0.86/7 0.918/2 0.943/54 6 54% 
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N2 Adenylosuccinate synthetase isozyme 2 P46664 0.761/13 0.762/3 0.752/18 4 12% 
N3 IMP DH 2 P24547 0.676/1 0.784/3 0.752/12 3 7% 
N4 3'(2')5'-bisphosphate nucleotidase 1 Q9Z0S1 1.262/48 1.042/85 0.439/5 7 29% 
  
      
  
  
      
  
E: energy metabolism 
     
  
E1 Transaldolase Q93092 0.912/54 1.047/73 0.842/48 6 20% 
E2a Aldose reductase P45376 1.054/57 1.206/2 1.306/9 7 28% 
E2b Aldose reductase P45376 1.25/17 1.42/11 1.95/1 7 26% 
E3a 6-phosphogluconateDH, decarboxylating Q9DCD0 1.135/47 1.258/7.7 1.305/3.8 8 20% 
E3b 6-phosphogluconateDH, decarboxylating Q9DCD0 1.08/60 1.33/5 1.25/17 14 35% 
E4 6-phosphofructokinase type C Q9WUA3 0.473/4 1.19/31 1.29/26 9 16% 
E5a enolase P17182 1.23/1 1.33/4 1.20/11 17 57% 
E5b enolase P17182 1.23/23 1.33/9 1.33/12 23 70% 
E5c enolase P17182 1.27/35 1.43/15 1.5/14 24 67% 
  
      
  
  
      
  
O: oxidative stress response 
     
  
O1 Neutrophil cytosol factor 4 P97369 0.991/95 1.061/72 0.53/3.3 7 28% 
O2 Glutamate-cysteine ligase reg.subunit O09172 1.631/7 1.644/2 1.837/3 5 22% 
O3 Flavin/biliverdin reductase (NADPH) Q923D2 1.571/7 1.126/46 1.467/7 6 39% 
O4 Peroxiredoxin-6 O08709 0.832/3 1.066/59 0.792/4 4 26% 
  
      
  
  
      
  
M: mitochondrion 
     
  
  
      
  
M1 Glutathione reductase. mitochondrial P47791 2.153/1 2.507/2 2.157/1 2 4% 
M2 Putative Clp protease. mitochondrial  O88696 1.408/8.6 1.342/4.2 1.007/95 4 18% 
M3 DLAT. mitochondrial Q8BMF4 0.566/7.7 1.046/76 1.2/6 2 5% 
  
 
 
    
  
  
      
  
P: proliferation 
     
  
P1 Replication protein A 32 kDa subunit Q62193 0.797/14 0.882/45 0.764/10 3 13% 
P2 DNA replication licensing factor MCM7 Q61881 1.45/2 1.17/11 1.13/50 15 28% 
  
      
  
  
      
  
T: translation 
     
  
T1 Methylthioribose-1-phosphate isomerase Q9CQT1 1.097/31 0.823/23 0.462/0.7 5 17% 
  
 
 
    
  
  
      
  
L: lysosome 
     
  
L1 Alpha-soluble NSF attachment protein Q9DB05 1.017/93 1.060/34 0.711/3 4 15% 
L2 Sorting nexin-2 Q9CWK8 0.843/10 0.901/42 0.729/2.1 11 25% 
L3 Synaptosomal-associated protein 23 O09044 0.613/4 0.580/7 0.464/1.5 3 22% 
  
      
  
  
      
  
 36 
U: Miscellaneous 
     
  
  
      
  
U1 EF-hand domain-containing protein D2 Q4FZY0 0.904/33 0.88/26 0.716/3.7 6 28% 
U2 RuvB-like 2 Q9WTM5 1.027/75 0.845/2 0.863/17 11 26% 
U3 
Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase 48 kDa subunit 
O54734 1.39/3 1.27/3 1.427/23 6 15% 
U4 Glia maturation factor beta Q9CQI3 0.824/31 0.692/6.4 0.755/4.2 4 31% 
U5 Transcription factor BTF-3 Q64152 1.44/28 1.34/21 1.57/5 4 38% 
            
 
  
 
 
*The accession numbers are those of the SwissProt Database. The proteins mentioned in the text are 
italicized in the table. The proteins validated directly or indirectly are in bold in the table.  
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Table4: Zinc-binding proteins identified in the metalloproteomic screen 
spot protein accession Mw IDA/PNS 
Nb. 
unique sequence 
ID name number* 
 
(fold/T-test) peptides coverage 
       Traffic and cytoskeleton 
     
       1 Actin-related protein 2/3 complex subunit 4  P59999 19667.4 5.6/0 3 18% 
2 Ran-specific GTPase-activating protein P34022 23597.1 1.28/10 4 21% 
3 F-actin-capping protein subunit alpha-1 P47753 32939.9 2.18/0.1 12 49% 
4 Actin-related protein 2 P61161 44761.7 5.1/0.2 14 36% 
5 Actin-related protein 2 P61161 44761.7 1.6/4.6 19 50% 
6 Actin-related protein 2 P61161 44761.7 1.04/73 12 32% 
7 F-actin-capping protein subunit beta P47757 33742.2 1.56/0.3 5 18% 
8 Gelsolin P13020 85941.9 1.77/0.4 37 47% 
       Energy metabolism 
     
       9 Isocitrate dehydrogenase [NAD] subunit alpha Q9D6R2 39639.4 1.97/10 8 25% 
10 Phosphoglycerate kinase 1  P09411 44551.1 3.45/0.2 28 64% 
11 Phosphoglycerate kinase 1 P09411 44551.1 2.23/0.4 34 77% 
12 6-phosphogluconate dehydrogenase  Q9DCD0 53248.8 1.86/0.3 22 38% 
13 6-phosphogluconate dehydrogenase Q9DCD0 53248.8 1.34/0.7 23 43% 
14 Transketolase P40142 67631.9 3.36/0.8 24 37% 
15 Transketolase P40142 67631.9 3.29/0.3 37 55% 
16 Phosphoglycerate mutase 1 Q9DBJ1 28804.8 3.39/0 12 43% 
17 Phosphoglycerate mutase 1 Q9DBJ1 28804.8 2.04/0.1 13 48% 
18 Glyceraldehyde-3-phosphate dehydrogenase P16858 35810.1 11.5/0 14 43% 
19 Glyceraldehyde-3-phosphate dehydrogenase P16858 35810.1 2.72/7 9 31% 
       Folding and chaperones 
     
       20 Peptidyl-prolyl cis-trans isomerase A P17742 17971.8 1.47/2.5 15 74% 
21 T-complex protein 1 subunit zeta P80317 58005.5 1.27/0.6 26 56% 
22 T-complex protein 1 subunit alpha P11983 60449.9 1.26/3.2 15 30% 
23 T-complex protein 1 subunit alpha P11983 60449.9 2.43/0.6 24 47% 
24 T-complex protein 1 subunit alpha P11983 60449.9 2.30/1.5 16 36% 
24 T-complex protein 1 subunit epsilon P80316 59625.6 
 
16 34% 
       Miscellaneous 
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25 Nucleoside diphosphate kinase A P15532 17208 1.84/4.5 14 76% 
26 Adenylyl cyclase-associated protein 1 P40124 51565.1 1.20/34 29 63% 
27 Adenylyl cyclase-associated protein 1 P40124 51565.1 1.74/0.2 31 72% 
 
 
*The accession numbers are those of the SwissProt Database.  
 39 
Table 5 : enzyme acitivities measured in control cell extracts and in extracts 
prepared from cells treated for 24 hours with either 8µg/ml zinc oxide, or 7µg/ml 
cationic zinc oxide, or 100µM zinc acetate. 
The activities are expressed in units/mg protein, the unit being defined as 1µmole of 
substrate converted per minute 
 
enzyme enolase 6PGDH biliverdin 
   
reductase 
ctrl 55.3±4.2 50.1±6.3 1.53±0.16 
Cationic ZnO 84.15±8.9 59.7±4.6 2.05±0.02 
ZnO 98±9.7 94.6±0.2 2.01±0.14 
Zn acetate 87±2.2 92.7±4.0 2.17±0.09 
    
 
6PGDH 
  0µM Zn 50.5±5.5 
  10µM Zn 33±2 
  15µM Zn 20±1 
  20µM Zn 9.5±0.75 
  25µM Zn 4.75±0.5 
   
 
